HONG KONG – Samsung Bioepis Co. Ltd. has inked a deal for the mainland China market with investment firm C-Bridge Capital Partners LLC, which will generate a new company: Affamed Therapeutics. The licensing agreement covers multiple biosimilar candidates from Samsung Bioepis. This includes its third-wave biosimilars SB-11 and SB-12, which are ranibizumab and eculizumab candidates based on Genentech Inc.'s Lucentis and Alexion Pharmaceuticals Inc.'s Soliris, respectively.